UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/528,377	01/04/2006	Jeffrey S. Glenn	STAN-316	7561	
77974 7590 12/18/2008 Stanford University Office of Technology Licensing Bozicevic, Field & Francis LLP			EXAMINER		
			LUCAS, ZACHARIAH		
1900 University Avenue Suite 200			ART UNIT	PAPER NUMBER	
East Palo Alto, CA 94303			1648		
			MAIL DATE	DELIVERY MODE	
			12/18/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/528,377	GLENN ET AL.		
Examiner	Art Unit		

		Zachanan Edda	1040	
	The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence address	
THE	REPLY FILED 10 September 2008 FAILS TO PLACE THI	IS APPLICATION IN CONDITION	FOR ALLOWANCE.	
1. 🛚	The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appetor Continued Examination (RCE) in compliance with 37 Coperiods:	replies: (1) an amendment, affidav eal (with appeal fee) in compliance	it, or other evidence, which places t with 37 CFR 41.31; or (3) a Reques	he
a)	The period for reply expiresmonths from the mailing	g date of the final rejection.		
b)	The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (ater than SIX MONTHS from the mailin (b). ONLY CHECK BOX (b) WHEN THI	g date of the final rejection.	
have under set fo may r	MONTHS OF THE FINAL REJECTION. See MPEP 706.07(sions of time may be obtained under 37 CFR 1.136(a). The date been filed is the date for purposes of determining the period of ex 37 CFR 1.17(a) is calculated from: (1) the expiration date of the srth in (b) above, if checked. Any reply received by the Office later educe any earned patent term adjustment. See 37 CFR 1.704(b) ICE OF APPEAL	on which the petition under 37 CFR 1. tension and the corresponding amount shortened statutory period for reply origon than three months after the mailing da	of the fee. The appropriate extension for inally set in the final Office action; or (2)	ee as
	The Notice of Appeal was filed on A brief in comp	oliance with 37 CFR 41.37 must be	filed within two months of the date of	of
	filing the Notice of Appeal (37 CFR 41.37(a)), or any externation Notice of Appeal has been filed, any reply must be filed water Noments	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Sinc	
3. 🛚	The proposed amendment(s) filed after a final rejection, I (a) They raise new issues that would require further co			
	(b) They raise the issue of new matter (see NOTE belo		,,	
	(c) They are not deemed to place the application in bet appeal; and/or	· ·	ducing or simplifying the issues for	
	(d) They present additional claims without canceling a NOTE: See Continuation Sheet. (See 37 CFR 1.1		ected claims.	
4. 🛛	, , , , , , , , , , , , , , , , , , , ,		empliant Amendment (PTOI -324)	
5.	•		(
6.			timely filed amendment canceling th	ne
7. 🛚	For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided that the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: 5.		ll be entered and an explanation of	
	Claim(s) rejected: <u>1,3,6-10,22 and 23</u> . Claim(s) withdrawn from consideration: <u>11-21</u> .			
AFFI	DAVIT OR OTHER EVIDENCE			
	The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			nd
	The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	overcome <u>all</u> rejections under appe y and was not earlier presented. S	al and/or appellant fails to provide a ee 37 CFR 41.33(d)(1).	l
	The affidavit or other evidence is entered. An explanatio UEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attached.	
11. 🏻	The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application in	n condition for allowance because:	
	Note the attached Information <i>Disclosure Statement</i> (s). Other:	(PTO/SB/08) Paper No(s)		
		/700hawiah		
		/Zachariah Lucas/ Primary Examiner, Art U	Jnit 1648	

Continuation of 3. NOTE: The claims combine limitations that were not previously combined.

.

Continuation of 11. does NOT place the application in condition for allowance because: The Applicant traverses the rejections of record on the basis that the Examiner has improperly applied the obvious to try standard. The Applicant asserts that the function of the NS4b protein was not known, and that therefore it would not have been obvious to target this protein with potential anti-HCV therapeutics.

The argument is not found persuasive. While the function of the NS4b protein was not known, it was nonetheless suggested by the Del Vecchio reference that the protein was an ATPase, and that the protein was therefore a potential target for anti-HCV drugs. The additional teachings of the secondary references render obvious to try the extension to additionally screening for drugs that inhibit NS4b GTP binding. Thus, knowledge in the art of the specific activity of the NS4b protein in the HCV life cycle was not required in order for those of ordinary skill to screen for the ability of inhibitors of NS4b GTPase activity to inhibit HCV replication. Those of ordinary skill in the art would have been able to pursue the known potential solutions (i.e. as to whether the compounds would inhibit HCV replication) with a reasonable expectation of success as means were available to those of ordinary skill in the art to determine if compounds inhibiting NS4b GTPase activity were effective in inhibiting HCV replication without knowledge of the specific function of the NS4b protein. For example, those of ordinary skill in the art could use HCV replication to determine the effect of the compounds on HCV replication.

For these reasons, and the reasons of record, the Applicant's arguments are not found persuasive. .